KLK3 and cancer: The overall 25-year progression-free, metastasis-free, and cancer-specific survival rates after anatomical radical prostatectomy were 68%, 84%, and 86%, respectively, although there were significant differences in treatment outcomes between men treated in the pre-PSA and PSA eras.